
Reporting Beyfortus to the Texas Immunization Registry: Data Quality Challenges 2024 Prageet Kaang; Vijaya Icchapurapu Access Resources Job AidEN About This presentation (slides) provides directions for reporting the use of Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) infection in infants in Texas. It describes challenges in data quality and how to report doses correctly. Beyfortus helps prevent severe RSV in young children but is not a vaccine. It explains how to enter information into the system and avoid errors when giving two doses on the same day or within 14 days. It also provides contact details for questions about reporting issues and resources for further reading on this topic. Tags Focus Area: Infectious Disease Audiences: Nurses; Physicians; Public Health Professionals Emergency Management Stage: Preparedness (Prevention / Protection) Keywords: Data Collection; Infant; Infant, Newborn; Registries; Respiratory Syncytial Virus Infections; Texas; Drug Approval; Immunization Programs; Respiratory Syncytial Virus, Human; Antibodies, Monoclonal, Humanized Institutions: Texas Department of State Health Services More like this Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health Federal Resource Toolkit for State and Local Agencies Serving Vulnerable Populations During the COVID-19 Emergency 2020 · ASPR TRACIE Nirsevimab Frequently Asked Questions None · American Academy of Pediatrics (AAP) The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Access Resources Job AidEN

Reporting Beyfortus to the Texas Immunization Registry: Data Quality Challenges

2024
Prageet Kaang; Vijaya Icchapurapu

Access Resources

Job AidEN

About

This presentation (slides) provides directions for reporting the use of Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) infection in infants in Texas. It describes challenges in data quality and how to report doses correctly. Beyfortus helps prevent severe RSV in young children but is not a vaccine. It explains how to enter information into the system and avoid errors when giving two doses on the same day or within 14 days. It also provides contact details for questions about reporting issues and resources for further reading on this topic.

More like this

Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health Federal Resource Toolkit for State and Local Agencies Serving Vulnerable Populations During the COVID-19 Emergency 2020 · ASPR TRACIE Nirsevimab Frequently Asked Questions None · American Academy of Pediatrics (AAP)

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Access Resources

Job AidEN

Reporting Beyfortus to the Texas Immunization Registry: Data Quality Challenges

Access Resources

About

Tags

More like this

Access Resources